Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betamethasone valerate + mupirocin is a topical combination drug used primarily to treat skin conditions characterized by both inflammation and bacterial infection. Betamethasone valerate is a synthetic corticosteroid that reduces inflammation, itching, redness, and swelling by suppressing the immune response and inhibiting the production of inflammatory mediators such as prostaglandins. Mupirocin is a topical antibiotic that inhibits bacterial protein synthesis by binding to bacterial isoleucyl-tRNA synthetase, effectively killing susceptible bacteria (notably Staphylococcus aureus and Streptococcus pyogenes) on the skin. This combination provides dual action—anti-inflammatory effects from betamethasone valerate and antibacterial effects from mupirocin—making it effective for conditions like infected eczema, impetigo with inflammation, infected contact dermatitis, secondarily infected psoriasis, wounds with secondary infection, lichen planus with superimposed infection, among others[1][2][3][4]. It is available in cream or ointment formulations for topical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone valerate + mupirocin.